The Serum Institute of India was halting the trial of the Oxford University-Astrazeneca COVID-19 vaccine in India until the British-Swedish drug maker restarts the trial. The move came a day after the Pune-based vaccine maker received a show-cause notice from the DGCI (Drug Controller's General of India). The central drug regulator had pulled up the company for not informing it about the pharma giant AstraZeneca pausing the clinical trials of the Oxford COVID-19 vaccine candidates in other countries. On 8th September 2020, the clinical trials of one of the Oxford-AstraZeneca's COVID-19 vaccine were suspended in the United Kingdom after a participant developed an unexplained illness.